Expert Insights in Advanced ALK-Positive NSCLCAddressing Questions Faced by

Physicians in Clinical PracticeSATURDAY, 28 SEPTEMBER 2019 | 18:30 – 20:00

VENUE: FIRA GRAN VIA, BARCELONA, SPAIN | ROOM: ALICANTE AUDITORIUM, HALL 3

MODERATOR

Enriqueta Felip, MD, PhDHead of Lung and Thoracic Oncology Units University Hospital Vall D’Hebron Barcelona, Spain

PANELISTS

Marina Chiara Garassino, MDChief of Medical Thoracic Oncology Unit Medical Consultant Medical Oncology Division Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy

Tony Mok, MD, FRCPCClinical Professor Department of Clinical Oncology The Chinese University of Hong Kong Hong Kong, China

Sanjay Popat, PhD, FRCPConsultant Medical Oncologist Royal Marsden Hospital Reader, Imperial College London London, United Kingdom

AGENDA

18:30IntroductionEnriqueta Felip, MD, PhD

18:35Expert Insights in 3 Patient Cases With Advanced ALK-Positive NSCLCEnriqueta Felip, MD, PhD

18:45The Patient Presenting With De Novo ALK-Positive Metastatic NSCLC: What Are the Best Options for Your Patient?Marina Chiara Garassino, MD and panel

19:05The Patient With ALK-Positive Metastatic NSCLC at Risk of CNS Progression: How Can We Determine and Reduce the Risk?Sanjay Popat, PhD, FRCP and panel

19:25The Patient Progressing After First Line Treatment With ALK-Targeted Therapy: What Are the Current Possibilities?Tony Mok, MD, FRCPC and panel

19:45Addressing Your QuestionsPanel

19:55Concluding RemarksEnriqueta Felip, MD, PhD

20:00Adjourn

ESMO 2019 INDUSTRY SATELLITE SYMPOSIUM

CPD

Refreshments offered by Medscape

Supported by an independent educational grant from Takeda.

This activity is certified for 1.5 CPD credits.